United Therapeutics Corp. Hits New 52-Week High at $537.11

United Therapeutics Corp. has reached a significant milestone by hitting a new 52-week high of USD 537.11 on February 25, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a mid-cap entity with a market capitalization of approximately USD 32,986 million. Over the past year, United Therapeutics has demonstrated impressive growth, with a remarkable 94.41% increase in stock price, significantly outperforming the S&P 500, which recorded a 12.95% gain during the same period. The company's strong financial metrics include a price-to-earnings (P/E) ratio of 25.00 and a return on equity (ROE) of 19.53%, indicating effective management and operational efficiency. Additionally, United Therapeutics has maintained a low debt-to-equity ratio of -0.42, reflecting a solid financial position. The company has consistently reported positive results for the last eight consecutive quarters, with operating cash flow reaching a high of USD 1,556.2 million. This performance highlights the company's strong long-term fundamentals and its position as a reliable performer in the market.